Cough and its importance in COPD

Smith, Jaclyn A.; Woodcock, Ashley

doi:10.2147/copd.2006.1.3.305

Cited by 49 publications

(45 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This difference probably explains the moderate correlation we found between psychological domain of LCQ and SPUT-SP domain of the CASA-Q. However, sputum production is likely to mechanically stimulate coughing 17 on one hand, and sputum wet weight was related to cough symptom evaluation by COU-SP part of the CASA-Q 11 on the other hand, which justifies the investigation of this hypothesized relationship.…”

Section: Discussionmentioning

confidence: 69%

Validation of the French version of the Leicester Cough Questionnaire in chronic obstructive pulmonary disease

et al. 2015

View full text Add to dashboard Cite

Cough is one of the three major symptoms reported by chronic obstructive pulmonary disease (COPD) patients. The Leicester Cough Questionnaire (LCQ) is a questionnaire exploring the impact of cough, but it does not exist in French. The aim of this study was to develop a French version of LCQ and to assess its psychometrics properties. A forward-backward translation process was used to develop the French version of the LCQ. COPD patients completed LCQ and Cough and Sputum Assessment Questionnaire (CASA-Q) to determine concurrent validity, content validity and internal consistency. Two weeks later, the LCQ was repeated to evaluate the reproducibility. Seventy-four COPD patients were recruited. The concurrent validity showed highly significant correlations between all scores of LCQ and CASA-Q (p < 0.001). The content validity was good with domain total scores correlations ranging from 0.918 to 0.953. The LCQ domains and total scores showed a very good internal consistency with Cronbach's a coefficients ranging between 0.802 and 0.917. The test-retest reliability was high in COPD patients with no change in cough. In conclusion, The French version of the LCQ is a valid and reliable instrument to measure health status in COPD patients.

show abstract

Section: Discussionmentioning

confidence: 69%

Validation of the French version of the Leicester Cough Questionnaire in chronic obstructive pulmonary disease

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Chronic respiratory problems were assessed using the following definitions: “Chronic respiratory disease diagnosed by a doctor, reported chronic cough, reported chronic phlegm, chronic bronchitis defined as cough and phlegm for >3 months per year since 2 years,27 cough and phlegm for >3 weeks and chronic wheezing”.…”

Section: Methodsmentioning

confidence: 99%

Motivation to quit smoking and acceptability of shocking warnings on cigarette packages in Lebanon

Layoun¹,

Salameh²,

Waked³

et al. 2017

PPA

View full text Add to dashboard Cite

IntroductionHealth warnings on tobacco packages have been considered an essential pillar in filling the gap of knowledge and communicating the health risks of tobacco use to consumers. Our primary objective was to report the perception of smokers on the textual health warnings already appearing on tobacco packages in Lebanon versus shocking pictures about the health-related smoking consequences and to evaluate their impact on smoking behaviors and motivation.MethodsA pilot cross-sectional study was undertaken between 2013 and 2015 in five hospitals in Lebanon. Participants answered a questionnaire inquiring about sociodemographic characteristics, chronic respiratory symptoms, smoking behavior and motivation to quit smoking. Only-text warning versus shocking pictures was shown to the smokers during the interview.ResultsExactly 66% of the participants reported that they thought shocking pictorial warnings would hypothetically be more effective tools to reduce/quit tobacco consumption compared to only textual warnings. Also, 31.9% of the smokers who were motivated to stop smoking reported that they actually had stopped smoking for at least 1 month secondary to the textual warnings effects. A higher motivation to quit cigarette smoking was seen among the following groups of smokers: males (odds ratio [OR] =1.8, P=0.02), who had stopped smoking for at least 1 month during the last year due to textual warning (OR =2.79, P<0.001), who considered it very important to report health warning on cigarette packs (OR =1.92, P=0.01), who had chronic expectoration (OR =1.81, P=0.06) and who would change their favorite cigarette pack if they found shocking images on the pack (OR =1.95, P=0.004).ConclusionLow-dependent smokers and highly motivated to quit smokers appeared to be more hypothetically susceptible to shocking pictorial warnings. Motivation to quit was associated with sensitivity to warnings, but not with the presence of all chronic respiratory symptoms.

show abstract

“…13 In addition, almost nothing is known about the effect of current first-line COPD treatments on symptoms of cough and sputum, and the need for studies to address this has been highlighted 12. Aclidinium bromide is a long-acting muscarinic antagonist (LAMA) that inhibits the action of acetylcholine at M3 receptors in the lungs, indirectly leading to airway smooth muscle relaxation.…”

Section: Introductionmentioning

confidence: 99%

Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials

et al. 2016

View full text Add to dashboard Cite

BackgroundCough and sputum are troublesome symptoms in chronic obstructive pulmonary disease (COPD) and are associated with adverse outcomes. The efficacy of aclidinium bromide 400 µg twice daily in patients with stable COPD has been established in two phase III studies (ACCORD COPD I and ATTAIN) and a phase IIIb active-comparator study. This analysis evaluated cough-related symptoms across these studies.MethodPatients were randomised to placebo, aclidinium 200 µg or 400 µg twice daily in ACCORD (12 weeks) and ATTAIN (24 weeks), or to placebo, aclidinium 400 µg twice daily or tiotropium 18 µg once daily (6-week active-comparator study). Analysed end points included changes from baseline in Evaluating Respiratory Symptoms (E-RS; formerly known as EXAcerbations of Chronic pulmonary disease Tool), total and cough/sputum scores and frequency/severity of morning and night-time cough and sputum symptoms.ResultsData for 1792 patients were evaluated. E-RS cough/sputum domain scores were significantly reduced with aclidinium 400 µg versus placebo in ATTAIN (−0.7 vs −0.3, respectively; p<0.01) and the active-comparator study (−0.6 vs −0.2, respectively; p<0.01). In the active-comparator study, significantly greater improvements were observed with aclidinium versus placebo for severity of morning cough (−0.19 vs −0.02; p<0.01) and phlegm (−0.19 vs −0.02; p<0.05). In ACCORD, aclidinium reduced night-time cough frequency (−0.36 vs 0.1 for placebo; p<0.001) and severity (−0.24 vs −0.1 for placebo; p<0.05), and frequency of night-time sputum production (−0.37 vs 0.05 for placebo; p<0.001).ConclusionsAclidinium 400 µg twice daily improves cough and sputum expectoration versus placebo in stable COPD.Trial registration numbersNCT00891462; NCT01001494; NCT01462929.

show abstract

Cough and its importance in COPD

Cited by 49 publications

References 51 publications

Validation of the French version of the Leicester Cough Questionnaire in chronic obstructive pulmonary disease

Validation of the French version of the Leicester Cough Questionnaire in chronic obstructive pulmonary disease

Motivation to quit smoking and acceptability of shocking warnings on cigarette packages in Lebanon

Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials

Contact Info

Product

Resources

About